Expand GMAB Menu
GMAB MENU

GMAB Latest Press Releases

-- July 23, 2026 --

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Business Wire 4:00 PM

-- July 15, 2026 --

Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2026 Globe Newswire 6:22 AM

-- July 6, 2026 --

Genmab Announces TEPKINLY (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma Business Wire 1:45 PM

-- June 29, 2026 --

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival Business Wire 4:15 PM
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival Globe Newswire 4:14 PM

-- June 15, 2026 --

Major Shareholder Announcement Globe Newswire 12:04 PM

-- June 13, 2026 --

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Business Wire 12:45 PM

-- June 11, 2026 --

Genmab Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients Business Wire 10:45 AM

-- May 21, 2026 --

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress Business Wire 5:00 PM

-- May 8, 2026 --

Major Shareholder Announcement Globe Newswire 3:05 PM

-- April 14, 2026 --

Major Shareholder Announcement Globe Newswire 10:44 AM
Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2026 Globe Newswire 6:22 AM

-- April 13, 2026 --

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S) in Combination with Bevacizumab in Advanced Ovarian Cancer Business Wire 9:35 AM

-- March 30, 2026 --

Major Shareholder Announcement Globe Newswire 12:00 PM
Market Data Delayed 15 Minutes